392 reports of this reaction
1.4% of all GENTAMICIN SULFATE reports
#20 most reported adverse reaction
MATERNAL EXPOSURE DURING PREGNANCY is the #20 most commonly reported adverse reaction for GENTAMICIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 392 FDA adverse event reports linking GENTAMICIN SULFATE to MATERNAL EXPOSURE DURING PREGNANCY. This represents approximately 1.4% of all 27,380 adverse event reports for this drug.
Patients taking GENTAMICIN SULFATE who experience maternal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MATERNAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for GENTAMICIN SULFATE, but still significant enough to appear in the safety profile.
In addition to maternal exposure during pregnancy, the following adverse reactions have been reported for GENTAMICIN SULFATE:
The following drugs have also been linked to maternal exposure during pregnancy in FDA adverse event reports:
MATERNAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 392 FDA reports for GENTAMICIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MATERNAL EXPOSURE DURING PREGNANCY accounts for approximately 1.4% of all adverse event reports for GENTAMICIN SULFATE, making it a notable side effect.
If you experience maternal exposure during pregnancy while taking GENTAMICIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.